Format
Sort by

Send to

Choose Destination

Links from Books

Items: 1 to 20 of 25

1.

Lead- and drug-like compounds: the rule-of-five revolution.

Lipinski CA.

Drug Discov Today Technol. 2004 Dec;1(4):337-41. doi: 10.1016/j.ddtec.2004.11.007.

PMID:
24981612
2.

P53 mdm2 inhibitors.

Khoury K, Dömling A.

Curr Pharm Des. 2012;18(30):4668-78. Review.

3.

Survey of the 2009 commercial optical biosensor literature.

Rich RL, Myszka DG.

J Mol Recognit. 2011 Nov-Dec;24(6):892-914. doi: 10.1002/jmr.1138.

PMID:
22038797
4.

Simultaneous in vitro molecular screening of protein-peptide interactions by flow cytometry, using six Bcl-2 family proteins as examples.

Simons PC, Young SM, Carter MB, Waller A, Zhai D, Reed JC, Edwards BS, Sklar LA.

Nat Protoc. 2011 Jun 9;6(7):943-52. doi: 10.1038/nprot.2011.339.

5.

Discovery, structure-activity relationship studies, and crystal structure of nonpeptide inhibitors bound to the Shank3 PDZ domain.

Saupe J, Roske Y, Schillinger C, Kamdem N, Radetzki S, Diehl A, Oschkinat H, Krause G, Heinemann U, Rademann J.

ChemMedChem. 2011 Aug 1;6(8):1411-22. doi: 10.1002/cmdc.201100094. Epub 2011 May 27.

PMID:
21626699
6.

A dual-readout F2 assay that combines fluorescence resonance energy transfer and fluorescence polarization for monitoring bimolecular interactions.

Du Y, Nikolovska-Coleska Z, Qui M, Li L, Lewis I, Dingledine R, Stuckey JA, Krajewski K, Roller PP, Wang S, Fu H.

Assay Drug Dev Technol. 2011 Aug;9(4):382-93. doi: 10.1089/adt.2010.0292. Epub 2011 Mar 11.

7.

HTRF: A technology tailored for drug discovery - a review of theoretical aspects and recent applications.

Degorce F, Card A, Soh S, Trinquet E, Knapik GP, Xie B.

Curr Chem Genomics. 2009 May 28;3:22-32. doi: 10.2174/1875397300903010022.

8.

A dual estrogen receptor TR-FRET assay for simultaneous measurement of steroid site binding and coactivator recruitment.

Hilal T, Puetter V, Otto C, Parczyk K, Bader B.

J Biomol Screen. 2010 Mar;15(3):268-78. doi: 10.1177/1087057109359196. Epub 2010 Feb 11.

PMID:
20150592
10.

Surface plasmon resonance based assay for the detection and characterization of promiscuous inhibitors.

Giannetti AM, Koch BD, Browner MF.

J Med Chem. 2008 Feb 14;51(3):574-80. doi: 10.1021/jm700952v. Epub 2008 Jan 9.

PMID:
18181566
11.
12.

Protein-protein interactions as targets for small molecule drug discovery.

Fry DC.

Biopolymers. 2006;84(6):535-52. Review.

PMID:
17009316
13.

Monitoring 14-3-3 protein interactions with a homogeneous fluorescence polarization assay.

Du Y, Masters SC, Khuri FR, Fu H.

J Biomol Screen. 2006 Apr;11(3):269-76.

PMID:
16699128
14.

Small-molecule inhibitors of protein-protein interactions: progressing towards the dream.

Arkin MR, Wells JA.

Nat Rev Drug Discov. 2004 Apr;3(4):301-17. Review. No abstract available.

PMID:
15060526
15.

A specific mechanism of nonspecific inhibition.

McGovern SL, Helfand BT, Feng B, Shoichet BK.

J Med Chem. 2003 Sep 25;46(20):4265-72.

PMID:
13678405
16.

Development and application of fluorescence polarization assays in drug discovery.

Burke TJ, Loniello KR, Beebe JA, Ervin KM.

Comb Chem High Throughput Screen. 2003 May;6(3):183-94. Review.

PMID:
12678697
17.

Fluorescence polarization: past, present and future.

Jameson DM, Croney JC.

Comb Chem High Throughput Screen. 2003 May;6(3):167-73. Review.

PMID:
12678695
18.

A comparison of ALPHAScreen, TR-FRET, and TRF as assay methods for FXR nuclear receptors.

Glickman JF, Wu X, Mercuri R, Illy C, Bowen BR, He Y, Sills M.

J Biomol Screen. 2002 Feb;7(1):3-10.

PMID:
11897050
19.

Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings.

Lipinski CA, Lombardo F, Dominy BW, Feeney PJ.

Adv Drug Deliv Rev. 2001 Mar 1;46(1-3):3-26. Review.

PMID:
11259830
20.
Items per page

Supplemental Content

Write to the Help Desk